Regeneron is among the most science and data focused biopharma and has a long, long history in genetics. They know how critical privacy is and will ensure the data are used to advance human health.

Potentially an even better home for the data than in the company, since now will not have pressure of quarterly reports.

No joke. I’ve seen it work wonders for providing meaning to many, including multiple rich-beyond-belief founders.

It's not clear why these data are just coming out now or what is different from the original trials run in this setting.

https://en.wikipedia.org/wiki/Lorlatinib

https://www.cancernetwork.com/view/durvalumab-significantly-...

For many, being a founder is not just "taking a risk on an unproven idea" it's also a career change from being a solo IC or technical leader to being an executive, with very, very different requirements for success, so the risk here is compounded.

Comments URL: https://news.ycombinator.com/item?id=38740649

Points: 6

# Comments: 1

It might be this is good at the end of the day. OpenAI is just not structured to win.

Alternative is Sam goes in house to MS who already have all the weights of GPT-4 and build again, but constrained by any existing charter.

I bet Sam goes and founds a company to take on OpenAI…and wins.

1. Most of the data cited stops around 2010, ignoring the huge progress that checkpoint inhibitors and cell therapies have made in many cancers.

2. Mixed up issues of treatment progress and treatment access. Treatment progress is a fact, but can be missed if patients don’t have access.

Access in the US is essentially a political issue - states with Medicaid expansion, for example, have better overall access than those that don’t. Also, in general, changing Medical practice is slow, even once a therapy is approved.

The narrative that we have only poor treatment options that don’t advance misses the true progress that has been made, and let’s those responsible, ie insurance companies and politicians off the hook.